Observational Program for Evaluation of Ribomustin Use in the First Line Therapy of Chronic Lymphocytic Leukemia
Phase of Trial: Phase IV
Latest Information Update: 25 Jun 2017
Price : $35 *
At a glance
- Drugs Bendamustine (Primary) ; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
- 27 Jun 2016 Status changed from active, no longer recruiting to completed.
- 19 Oct 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov record.